CRISPR-based gene editing for antimicrobial resistance control in human medicine.
Alvi AA, Hussain M, Noureen S, Malik ZA, Zahoor S
Crispr
The same CRISPR toolkit now entering human clinical trials for drug-resistant infections is already being adapted by plant breeders to engineer disease resistance in crops — knowing how it works in medicine now gives you a head start on understanding what's coming to your seed catalog and dinner garden.
Antibiotic-resistant bacteria are becoming one of medicine's biggest threats, and traditional antibiotics are losing the arms race. Scientists are now using a precise gene-editing tool called CRISPR to find and disable the specific genetic instructions that let bacteria shrug off antibiotics — without harming the beneficial microbes living alongside them. Two experimental treatments using this approach are already being tested in human volunteers.
Key Findings
Drug-resistant bacteria directly caused approximately 1.27 million deaths in 2019 alone, with projections of 1.91 million annual deaths by 2050 if trends continue.
CRISPR-Cas systems (Cas9, Cas12a, Cas3, Cas13) can selectively kill pathogens or restore antibiotic sensitivity by disrupting resistance genes, avoiding the broad collateral damage of conventional antibiotics.
Two clinical-stage candidates — SNIPR001 (Phase I/II, NCT05277350) and LBP-EC01 (Phase 2/3, NCT05488444) — represent the most advanced human trials of CRISPR-based antimicrobials to date.
chevron_right Technical Summary
Scientists are developing CRISPR gene-editing tools to precisely disarm antibiotic-resistant bacteria in human patients — targeting resistance genes directly rather than killing bacteria broadly. Two clinical trials are already underway, marking a potential turning point against a crisis projected to kill nearly 2 million people per year by 2050.
Abstract Preview
Antimicrobial resistance (AMR) has already become one of the most urgent threats to the public health of this century. In 2019 alone, it directly causes about 1.27 million deaths and it was estimat...
open_in_new Read full abstractAbstract copyright held by the original publisher.
Was this useful?
Want to tell us more? (optional)
Thanks for the note!
Something went wrong — please try again.
Too many submissions. Try again in an hour.
Chloroplast Genome Editing Eliminates Gluten Immunogenicity in Triticum aestivum
It could mean that people with celiac disease — roughly 1 in 100 worldwide — may one day safely eat bread made from real wheat, without sacrificing the taste...